Central Asian Research Index

West Kazakhstan Regenerative Medicine Journal, 2025, т. 13, № 4, с. 178-185

Ex Vivo mRNA-loaded Dendritic Cell Vaccines for Cancer Immunotherapy

Fariborz Nowzari, Farhad Nowzari, Mohammadsaeid Zahedi, Kiana Samimi, Mehdi Kian, Alireza Karimzadeh, Nader Tanideh

Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Kaufland e-commerce, Germany
Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
Division of Immunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
Department of Comparative Biomedical Sciences, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Аннотация · Abstract

This scoping review examines the role of ex vivo dendritic cell (DC) mRNA vaccines in cancer immunotherapy from 2015 to 2025, with a focus on their dominance in glioblastoma trials and strategies to enhance immunogenicity and delivery. Analyzing 32 clinical trials identified through PubMed and ClinicalTrials.gov, the review highlights the vaccines’ mechanisms, safety profiles, and clinical progress, particularly in brain/central nervous system cancers (18/32 trials). Key strategies include antigen engineering with tumor-associated antigens (e.g., Wilms’ tumor 1, telomerase reverse transcriptase, and pp65) and personalized neoantigens, improved antigen processing through lysosomal-associated membrane protein sequences and PD-L1/L2 silencing, and combination therapies with immune checkpoint inhibitors, cytokines, chemotherapy, and cellular therapies (24/32 trials). Delivery optimization, including intradermal administration and preconditioning with tetanus–diphtheria toxoid or lymphodepletion, addresses migration challenges but reveals gaps in standardization. Future directions involve integrating DC vaccines with other modalities and leveraging machine learning for personalized regimens.

Сведения · Details